Background

Chronic wounds inflate healthcare costs and complicate patient healing. Biofilms are a recurring cause of such wounds due to their resilience to antibiotics. Currently, there are no outstanding treatments. The standard of care is debridement followed by antibiotics, however these infections can be hard to treat because of the biofilms. This is in part because the extra polymeric substance (EPS), which is the backbone of biofilms, creates physical and chemical barriers to antibiotics.

Technology Overview

This technology is a specific combination of enzymes that have the ability to dismantle and degrade the biofilm EPS infrastructure done in combination with an antibiotic. This can facilitate the healing process without the downside of debridement.

Further Details

Derek Fleming & Kendra Rumbaugh,